Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDVRG.L Regulatory News (DVRG)

  • There is currently no data for DVRG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Labskin contract

4 Oct 2022 07:00

RNS Number : 5975B
Deepverge PLC
04 October 2022
 

 

4 October 2022

 

DeepVerge PLC

 

("DeepVerge" or "the Company")

 

 

Labskin contract to develop revolutionary new approach to testing for radiation exposure

 

Collaboration with team of experts to develop new standards to protect military and civilians working or living near radiation sources

 

Labskin, a DeepVerge (AIM:DVRG) business, announces its selection by the Intelligence Advanced Research Projects Activity ("IARPA"), part of the US Office of the Director of National Intelligence, to join a team of experts to develop new ways to evaluate radiation exposure in civilians and military personnel. 

 

Labskin is a key member of a consortium selected to develop these technologies in collaboration with a multidisciplinary team of experts including professors from the University of Columbia in New York, Georgetown University in Washington DC, the Georgia Institute of Technology, scientists from the American Type Culture Collection ("ATCC") and computer scientists and researchers from ARETE Associates, a defence contractor specialising in sensing solution and machine learning algorithms.

 

In a 3-year project worth $810k to the Company, starting immediately, Labskin will help develop this technology into minimally invasive testing for radiation for a programme known as Targeted Evaluation of Ionizing Radiation Exposure ("TEI-REX"). TEI-REX aims to develop novel approaches to evaluate organisms exposed to low-dose ionising radiation. Labskin, coupled with Skin Trust Club's expertise in skin research and microbiology, is essential for the project.

 

The goal of the project is to develop a new biodosimetry standard which could be applied to maintain the safety of military and civilian populations working or living in close proximity to ionizing radiation sources, such as: nuclear plants, nuclear vessels, ammunition, etc. Labskin's contribution is the creation of a simple non-invasive swab test to collect signatures from the skin surface that allows machine learning algorithms to detect and quantify the impact of any amount of radiation exposure on the skin microbiome.

 

David Caballero-Lima, Chief Scientist, Labskin commented:

"This is a unique opportunity to revolutionise the way we test for radiation exposure. Labskin and Skin Trust Club are at the forefront of an increasing number of cutting edge technologies that are changing our world. This technique can also be applied to detect the impact of pollution or a variety of chemicals on the environment. This type of testing could also be used to detect exposure in complex ecological systems such as the soil, crops or sediments."

 

Colin O'Sullivan, Chief Information Officer, Labskin commented:

"We are committed to the success of this very exciting project. The inclusion of artificial intelligence and the opportunity to work with ARETE Associates, with their vast experience in complex AI applications, will result in further advances in how AI can be used in conjunction with our skin model at scale. This project coincides with the expansion of our US labs in Delaware, which will assist in the implementation of this large project. We believe our proven ability to transition technology to the field with Skin Trust Club will be invaluable as we progress this project."

 

DeepVerge plc

Gerard Brandon, CEO

+44 (0) 7340 055 648

SPARK Advisory Partners Limited

(Nominated Adviser)

Neil Baldwin/Andrew Emmott

+44 (0) 113 370 8974

Turner Pope Investments (TPI) Limited (Broker)

Andy Thacker/James Pope

+44 (0) 20 3657 0050

 

 

About DeepVerge

DeepVerge is an environmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments for the analysis and identification of bacteria, viruses and toxins. Utilizing artificial intelligent data analytics to scientifically prove the impact of skincare product claims on skin microbiome for most of the top 20 global cosmetic company clients and remotely detect and identify in real-time, dangerous pathogens in wastewater treatment plants, drinking water, rivers, lakes and reservoirs.

 

Labskin (Life Science Division)

Labskin have been pioneering the development of laboratory grown human skin platform for more than 15 years and is the only commercially available lab-grown full thickness human skin model that naturally mimics the skin's microbiome. With top 20 global consumer health and skincare clients, thousands of industry tests, the good and bad bacteria that naturally exists on human skin is present on Labskin when testing skin care, cosmetics, health care, drug delivery or wound care products. The Labskin test platform and protocols help clients maintain an optimum real-world environment, when testing their new ingredients and existing skincare products, that shows the positive or negative impact on skin's natural microflora.

 

Skin Trust Club

Skin Trust Club (www.skintrustclub.com), launched in 2021, provides customized skincare routines derived from a home test kit, lab tested and linked to local environment via a free smartphone App that updates in real-time and identifies skincare products that suit the subscribers unique skin microbiome. This revolutionizes how you take care of your skin with your own skincare routine. The Home Test Kit comprises a single swab that maps the skin microbiome delivering a report that produces the most appropriate daily skincare routine based on science, not guesswork. Using real-time air pollution and weather data from the customer's location, the Skin Trust App builds a complete picture of the skin microbiome and the impact of local surroundings.

 

About Reach announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEADEDEAPAFFA
Date   Source Headline
1st Feb 20218:30 amRNSAppointment of former IBM Legal Counsel as CoSec
1st Feb 20217:00 amRNSAppointment of former IBM Legal Counsel as CoSec
25th Jan 20212:22 pmRNSExercise of Warrants and Total Voting Rights
18th Jan 20214:51 pmRNSExercise of Options and Total Voting Rights
15th Jan 20217:00 amRNSCompletion of Compulsory Acquisition; TVR
11th Jan 20217:00 amRNSDVRG confirms maiden Q4 profit;guides £10m in 2021
11th Dec 20207:00 amRNSNew Labskin service - update
3rd Dec 20204:26 pmRNSDirector/PDMR Shareholding
1st Dec 20207:00 amRNSTrading Update & Investor Presentation
27th Nov 20207:00 amRNSInterim analysis from Aberdeen Uni - Labskin study
25th Nov 20207:00 amRNSInvestor presentation and corporate update
23rd Nov 20209:26 amRNSHolding(s) in Company
19th Nov 20205:25 pmRNSIssue of Share Options/PDMR Dealings
18th Nov 202012:17 pmRNSTR-1: Notification of major holdings
18th Nov 202011:06 amRNSSecond Price Monitoring Extn
18th Nov 202011:00 amRNSPrice Monitoring Extension
17th Nov 20203:43 pmRNSDirector/PDMR Shareholding
17th Nov 20203:38 pmRNSAllotment of Shares Following Close of Offer
16th Nov 20207:00 amRNSUpdate on detection products
13th Nov 20205:22 pmRNSHolding(s) in Company
10th Nov 20202:57 pmRNSExercise of Warrants and Total Voting Rights
10th Nov 20201:14 pmRNSExchange and Grant of Options and Warrants
10th Nov 20207:00 amRNSAppointment of Non-Executive Director
9th Nov 20205:30 pmRNSDeepverge
9th Nov 20205:02 pmRNSAllotment of Shares and Level of Acceptances
9th Nov 20202:05 pmRNSSecond Price Monitoring Extn
9th Nov 20202:00 pmRNSPrice Monitoring Extension
9th Nov 20208:46 amRNSHolding(s) in Company
9th Nov 20208:06 amRNSOffer Unconditional in all respects
3rd Nov 20203:00 pmRNSOFFER UNCONDITIONAL AS TO ACCEPTANCES; EXTENDED
26th Oct 20206:31 pmRNSForm 8.3 - Deepverge PLC
23rd Oct 20204:41 pmRNSSecond Price Monitoring Extn
23rd Oct 20204:35 pmRNSPrice Monitoring Extension
23rd Oct 20204:08 pmRNSComment on detection of COVID-19 in UK Sewage
22nd Oct 20204:40 pmRNSSecond Price Monitoring Extn
22nd Oct 20204:35 pmRNSPrice Monitoring Extension
22nd Oct 20209:05 amRNSSecond Price Monitoring Extn
22nd Oct 20209:00 amRNSPrice Monitoring Extension
13th Oct 20203:55 pmRNSPublication of Offer Document; Rule 15 letters
13th Oct 20203:45 pmRNSReplacement - Form 8 (OPD) - Modern Water plc
9th Oct 20207:00 amRNSUpdate on Offer for Modern Water plc by DeepVerge
7th Oct 20204:40 pmRNSSecond Price Monitoring Extn
7th Oct 20204:35 pmRNSPrice Monitoring Extension
7th Oct 20202:05 pmRNSSecond Price Monitoring Extn
7th Oct 20202:00 pmRNSPrice Monitoring Extension
7th Oct 202011:05 amRNSSecond Price Monitoring Extn
7th Oct 202011:00 amRNSPrice Monitoring Extension
7th Oct 20209:05 amRNSSecond Price Monitoring Extn
7th Oct 20209:00 amRNSPrice Monitoring Extension
6th Oct 20205:21 pmRNSForm 8.3 -Deepverge PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.